<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04394637</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00236647</org_study_id>
    <nct_id>NCT04394637</nct_id>
  </id_info>
  <brief_title>Ultra High Resolution CT to Assess Role of Intramyocardial Fat and Delayed Enhancement in Ventricular Arrhythmogenesis</brief_title>
  <official_title>Ultra High Resolution CT to Assess Role of Intramyocardial Fat and Delayed Enhancement in Ventricular Arrhythmogenesis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canon Medical Systems, USA</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research is being done to determine how well cardiac computed tomography (CT) scanning&#xD;
      measures of fat within the heart can predict abnormal heart rhythms and how well cardiac CT&#xD;
      can measure scar within the heart versus cardiac magnetic resonance imaging (MRI).&#xD;
&#xD;
        -  People who have been enrolled in PROSe-ICD (NA_00045142) and Reynolds (NA_00037404)&#xD;
           studies may join&#xD;
&#xD;
        -  The procedures, tests, drugs or devices that are part of this research and will be paid&#xD;
           for by the study&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators aim to investigate the role of intramyocardial fat on ventricular&#xD;
      arrhythmogenesis. Intramyocardial fat deposition has been frequently observed in patients&#xD;
      with ischemic heart disease and is readily detectable by multi-detector computed tomography&#xD;
      (MDCT) with high sensitivity and specificity, unlike other modalities. Like intramyocardial&#xD;
      fat, reentrant ventricular tachycardia (VT) tends to occur late after the onset of myocardial&#xD;
      infarction and the investigators hypothesize that lipomatous metaplasia within the infarct&#xD;
      may precipitate later onset ventricular arrhythmias (VA). Prior studies have shown that&#xD;
      intramyocardial fat correlates with slow myocardial conduction velocity and with critical&#xD;
      circuits for VA but the investigators do not know the causal relationship between&#xD;
      intramyocardial fat and future risk of VA.&#xD;
&#xD;
      Intramyocardial fat deposition or lipomatous metaplasia has been frequently observed in&#xD;
      patients with ischemic heart disease and is readily detectable by multi-detector computed&#xD;
      tomography (MDCT) with high sensitivity and specificity. Like intramyocardial fat, reentrant&#xD;
      ventricular tachycardia (VT) tends to occur late after the onset of myocardial infarction and&#xD;
      the investigators hypothesize that there may be a causal relationship. Prior studies have&#xD;
      shown that intramyocardial fat correlates with slow myocardial conduction velocity and with&#xD;
      critical circuits for VT in patients referred for VT ablation who already manifest VA.&#xD;
&#xD;
      However, the correlation of intramyocardial fat on CT with late gadolinium enhancement (LGE)&#xD;
      on cardiac magnetic resonance (CMR) in a general population of patients with ischemic&#xD;
      cardiomyopathy with no prior history of VA has not been reported. Specifically, it is unknown&#xD;
      whether the presence, distribution and/or volume of fat is an independent predictor of VA.&#xD;
      Further CMR is less widely available in medical centers, and is more expensive with longer&#xD;
      scanning times compared to CT. CT provides higher spatial resolution, is widely available and&#xD;
      is not as susceptible to magnetic interference from internal cardiac defibrillator (ICD)&#xD;
      generators and thus makes it an attractive imaging modality for risk stratification,&#xD;
      particularly longitudinally over time.&#xD;
&#xD;
      Hypothesis: The investigators' objective is to define the prevalence and distribution of&#xD;
      intramyocardial fat in patients with ischemic heart disease scheduled for or with in-situ&#xD;
      implantable defibrillators. Further, the investigators aim to assess the independent&#xD;
      association of intramyocardial fat with VA and determine whether it adds any utility above&#xD;
      LGE measured by CMR. Finally, the investigators will assess how well delayed enhanced CT&#xD;
      correlates with LGE on MRI and test its association with ventricular arrhythmias.&#xD;
&#xD;
      Importance: The significance of the investigators' research is that the investigators will:&#xD;
      1) test whether intramyocardial fat on CT can be used as a non-invasive tool for sudden&#xD;
      cardiac death risk stratification in patients who have or are scheduled to undergo ICDs, and&#xD;
      2) define whether delayed enhancement CT is comparable to the current non-invasive gold&#xD;
      standard of CMR for identifying myocardial scar.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">March 4, 2021</start_date>
  <completion_date type="Anticipated">May 2023</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of intramyocardial fat in patients with ischemic heart disease</measure>
    <time_frame>2 years</time_frame>
    <description>The primary aim is to test whether intramyocardial fat on MDCT is as effective or adds additional utility to risk stratification for VA above that of CMR-LGE characteristics in ischemic cardiomyopathy patients who are candidates for ICD therapy or have in situ ICDs.&#xD;
Our objective is to define the prevalence and distribution of intramyocardial fat in patients with ischemic heart disease scheduled for or with in-situ implantable defibrillators. Further, we aim to assess the independent association of intramyocardial fat with VA and determine whether it adds any utility above LGE measured by CMR.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Prevalence of delayed enhanced CT detected scar</measure>
    <time_frame>2 years</time_frame>
    <description>Comparison of the scar distribution on delayed enhanced CT with LGE on cardiac MRI.&#xD;
The significance of our research is that we will test whether delayed enhanced CT can be used as a non-invasive tool for sudden cardiac death risk stratification in patients with ischemic heart disease and whether delayed enhancement CT is comparable to the current non-invasive gold standard of CMR for identifying myocardial scar.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quantification of delayed enhanced CT detected scar</measure>
    <time_frame>2 years</time_frame>
    <description>Comparison of the scar distribution on delayed enhanced CT with LGE on cardiac MRI.&#xD;
The significance of our research is that we will test whether delayed enhanced CT can be used as a non-invasive tool for sudden cardiac death risk stratification in patients with ischemic heart disease and whether delayed enhancement CT is comparable to the current non-invasive gold standard of CMR for identifying myocardial scar.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Ventricular Arrhythmias</condition>
  <arm_group>
    <arm_group_label>PROSe-ICD</arm_group_label>
    <description>PROSe-ICD [NCT00733590/ Institutional Review Board (IRB) NA_00045142], a large prospective cohort study of patients who received an ICD for primary prevention.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reynolds study</arm_group_label>
    <description>Functional Energetics (Reynolds study, NA_00037404), a study with conventional contrast-enhanced 1H MRI to determine ventricular geometry, global and regional function, as well as infarct size characteristics following delayed contrast enhancement.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        The investigators will recruit patients with a history of an ischemic cardiomyopathy from&#xD;
        the current PROSe-ICD to undergo a cardiac CT performed using an ultra-high-resolution&#xD;
        (UHR) CT scanner (Canon, Precision) using iodinated contrast for (a) identification of&#xD;
        myocardial fat, and (b) myocardial scar visualization (areas of delayed contrast&#xD;
        enhancement).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients aged 18 or older with history of ischemic cardiomyopathy enrolled in the&#xD;
             current Reynolds study or PROSe-ICD study will be asked to participate&#xD;
&#xD;
          -  Women of child bearing potential must demonstrate a negative pregnancy test within 24&#xD;
             hours of the study CT&#xD;
&#xD;
          -  Ability to understand and willingness to sign the Informed Consent Form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known allergy to iodinated contrast media&#xD;
&#xD;
          -  Patients with glomerular filtration rate (GFR) â‰¤ 30 mL/min will not be enrolled in the&#xD;
             study due to the use of intravenous iodinated contrast agents&#xD;
&#xD;
          -  Atrial fibrillation or uncontrolled tachyarrhythmia&#xD;
&#xD;
          -  Evidence of severe symptomatic heart failure (NYHA Class III or IV)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan Chrispin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins Medical Institute</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>May 14, 2020</study_first_submitted>
  <study_first_submitted_qc>May 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 19, 2020</study_first_posted>
  <last_update_submitted>March 24, 2021</last_update_submitted>
  <last_update_submitted_qc>March 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ischemic Cardiomyopathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arrhythmias, Cardiac</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

